Medical tech firm Enovis' Q2 sales beat expectations

Enovis

07/08/2025 11:18

Overview

Enovis Q2 net sales grow 7%, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 beats consensus, indicating strong operational performance

Company reports Q2 net loss of $37 mln, reflecting profitability challenges

Outlook

Enovis expects 2025 revenue between $2.245 bln and $2.275 bln

Company forecasts 2025 adjusted EBITDA of $392-402 mln

Enovis updates full-year adjusted EPS guidance to $3.05-$3.20

Result Drivers

RECONSTRUCTIVE SALES - Reconstructive segment sales grew 11% year-over-year, driven by new product introductions

STABLE MARKETS - Stable end markets contributed to overall sales growth of 7%

NEW PRODUCTS - Encouraging momentum in new product introductions supported sales growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$564.54 mln
$554.60 mln (11 Analysts)
Q2 Adjusted EPS
Beat
$0.79
$0.72 (11 Analysts)
Q2 Gross Margin
59.3%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Enovis Corp is $57.00, about 54.8% above its August 6 closing price of $25.76

Press Release: ID:nGNX6cwhG7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)